Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05005338 · ClinicalTrials.gov registry record · Phase 1
A Study to Determine the Absolute Bioavailability of BIIB122/DNL151 in Healthy Subjects
A Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT05005338 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 8 participants.
The verdict
NCT05005338, a Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a single center, non-randomized, open label Phase 1 study to determine the PK and absolute bioavailability of BIIB122 (DNL151) in 2 conditions: following a single, oral dose of BIIB122 (DNL151) and following consecutive days of oral dosing, approximating steady state.
Interventions
- DRUG [14C] BIIB122 ([14C] DNL151)
- DRUG BIIB122 (DNL151)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2021-07-28 |
| Est. Completion | 2021-09-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05005338
The ClinicalTrials.gov registry entry for NCT05005338 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which [14C] BIIB122 ([14C] DNL151) is the first listed.
NCT05005338 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05005338 about?
NCT05005338 is a clinical study titled "A Study to Determine the Absolute Bioavailability of BIIB122/DNL151 in Healthy Subjects". This is a single center, non-randomized, open label Phase 1 study to determine the PK and absolute bioavailability of BIIB122 (DNL151) in 2 conditions: following a single, oral dose of BIIB122 (DNL151) and following consecutive days of oral dosing, approximating steady state.
What is the current status of trial NCT05005338?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2021-07-28. Estimated completion is 2021-09-23.
What interventions are being tested in trial NCT05005338?
The interventions under investigation include: [14C] BIIB122 ([14C] DNL151) (DRUG), BIIB122 (DNL151) (DRUG).
Who is sponsoring clinical trial NCT05005338?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.